What Is the Prognosis for Kidney Cancer Spread to the Lungs?

Kidney cancer that has spread to the lungs carries a wide range of outcomes, from median survival times under two years in high-risk patients to five-year survival above 50% for carefully selected individuals treated with surgery or newer immunotherapy combinations. The lungs are the single most common destination for metastatic renal cell carcinoma, involved in more than half of patients at the time metastatic disease is first detected. That frequency, paradoxically, is partly why the science here is more developed than for many other metastatic patterns: there is a large body of research on lung-specific treatment options and the factors that push prognosis in one direction or the other.

Why Kidney Cancer So Often Lands in the Lungs

The kidneys filter an enormous volume of blood, and the venous drainage from a kidney tumor feeds directly into the inferior vena cava and then the right side of the heart, which pumps that blood straight into the pulmonary capillary beds. This anatomical plumbing makes the lungs a natural first stop for circulating tumor cells. In one series of 151 metastatic renal cell carcinoma patients, about 56% had pulmonary metastases at the time their metastatic disease was identified.¹ Some patients present with lung nodules found incidentally on imaging before they even know about their kidney tumor. Others develop pulmonary deposits months or years after having a kidney removed.

How Doctors Estimate Survival

Oncologists do not look at “stage IV kidney cancer” as a single category. They slot patients into risk groups using scoring systems that weigh clinical and laboratory factors such as physical performance, time from diagnosis to treatment, blood counts, and calcium and hemoglobin levels. The two most widely used models are the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score and the Memorial Sloan Kettering Cancer Center (MSKCC) model.

These risk scores separate patients into favorable, intermediate, and poor categories, and the survival differences are dramatic. In one multi-institutional study of metastatic non-clear-cell cases, median cancer-specific survival under the IMDC model was 41 months for favorable-risk patients, 21 months for intermediate, and 8 months for poor-risk patients.² A separate Turkish cohort, which included predominantly clear-cell histology, reported even longer overall survival figures: median overall survival of 75 months for favorable-risk patients, roughly 48 months for intermediate, and about 18 months for poor risk under the IMDC model.³ The wide gap between these two datasets underscores an important point: the predominant cell type (clear cell versus non-clear cell) and the era of treatment both shape how far these numbers stretch.

These models are imperfect, of course. Their concordance indices, a measure of how well the score matches actual outcomes, hover in the range of 0.61 to 0.66, meaning they get the ordering right about two-thirds of the time.⁴ That is useful but far from perfect, and individual patients regularly outperform or underperform what their risk group predicts.

Factors That Shift the Outlook for Lung Metastases Specifically

Within the population of kidney cancer patients whose disease has reached the lungs, several factors matter beyond the general risk score.

The disease-free interval, meaning the time between removal of the original kidney tumor and the appearance of lung deposits, is one of the strongest predictors. In a 25-year surgical series, patients whose lung metastases appeared two or more years after nephrectomy had a five-year survival of 58%, compared with 26% for those whose metastases appeared within the first two years.⁵ A longer gap before metastasis suggests slower-growing biology, which tends to respond better to local treatments and carries a less aggressive trajectory overall.

The number and size of lung nodules also matter. One large surgical study found that patients with fewer than seven pulmonary metastases had a five-year survival of about 47%, versus roughly 15% for those with more than seven.⁶ Similarly, metastases under 2 cm in diameter have been linked to better disease-free intervals and higher survival after surgical removal.⁷

Interestingly, whether the lung metastases appear at the same time as the kidney cancer or later (synchronous versus metachronous) and whether they sit in one lung or both did not reach statistical significance in at least one retrospective study. What did matter was whether the metastases were confined to a single lobe versus spread across multiple lobes.⁸ This is a useful distinction because imaging often shows bilateral nodules that still happen to be limited to one lobe per side, a pattern that carries a different prognosis than diffuse multilobar involvement.

Surgery to Remove Lung Metastases

When kidney cancer spreads only to the lungs and the number of lesions is limited, surgeons can sometimes physically remove every visible deposit, a procedure called pulmonary metastasectomy. This is not an option for everyone, but in selected patients the results are encouraging.

One Italian center reported five-year and ten-year overall survival rates of 75% and 59% from the date of the first lung metastasectomy.⁷ These are highly selected patients, typically with a long disease-free interval, good physical condition, and a small number of resectable nodules, so these numbers should not be taken as representative of all patients with lung metastases. The key prognostic factors in that series were metastasis size (under 2 cm fared better) and a disease-free interval of five years or more.

A larger German series of 191 patients reported a more sobering five-year survival of about 37% overall, with a sharp split between those who had a complete resection (roughly 42%) and those with incomplete resection (about 22%).⁶ The presence of lymph node metastases in the chest dragged the five-year rate down to about 24% even after complete resection, compared with 42% without lymph node involvement. Completeness of resection and the disease-free interval were the two strongest independent predictors in multivariate analysis from the Japanese 25-year series as well.⁵

Immunotherapy and Targeted Drug Therapy

The treatment landscape for metastatic kidney cancer has shifted substantially in the past decade. First-line systemic treatment for metastatic renal cell carcinoma now typically involves immune checkpoint inhibitors targeting PD-1, combined either with another checkpoint inhibitor or with an antiangiogenic drug.⁹ These combinations have extended overall survival compared with older single-agent approaches, and response rates vary by the specific regimen.

For patients on tyrosine kinase inhibitors (TKIs), which block the blood-vessel growth that tumors rely on, a subset achieves long-term disease control. In one study, long-term responders, those who remained progression-free for 36 months or more on a TKI, had a median progression-free survival of 70 months, compared with 10 months in shorter responders. Prior nephrectomy, good physical performance, and the absence of liver metastases were the factors that best predicted a long-term response.¹⁰ That last factor, lack of liver involvement, is relevant for patients with lung-only metastases: having the disease confined to the lungs rather than also in the liver or bones tends to be a more favorable profile for systemic therapy.

Stereotactic Radiation for Lung Deposits

Not every patient is a good candidate for open surgery, whether because of the number or location of their nodules, their overall health, or their preference. Stereotactic body radiotherapy (SBRT) delivers high-dose, precisely targeted radiation over a few sessions and has become an important tool for lung metastases from kidney cancer that are limited in number, a situation oncologists call oligometastatic disease.

A multicenter German analysis of SBRT for pulmonary metastases from renal cell carcinoma reported one-year and three-year local control rates of 98% and 92%, with one-year and three-year overall survival of 84% and 44%.¹¹ Larger metastases and worse physical performance predicted shorter survival. A more recent single-institution study found even stronger results: two-year local control of 97%, with median overall survival of about 66 months and five-year survival of 53%.¹² Local failure was rare in both series, with most disease progression occurring at new sites elsewhere in the body rather than regrowth of treated lesions. Toxicity was mild.

Radiofrequency ablation (RFA), which destroys tumors with heat delivered through a needle, is another minimally invasive option. A center with over a decade of experience using RFA for kidney cancer lung metastases found it to be effective and safe, often combined with or followed by systemic therapy. RFA can be repeated if new nodules appear, and it may delay the need for systemic treatment in some patients.¹³

Histological Subtype Makes a Real Difference

Most kidney cancers are clear cell renal cell carcinoma, but papillary and chromophobe subtypes account for a meaningful minority. When it comes to lung metastases, the subtype changes the picture in ways that are not always intuitive.

A large analysis published in JAMA Network Open found that papillary renal cell carcinoma patients had worse survival than clear cell patients across all metastatic sites. Chromophobe tumors, which generally carry a better prognosis than clear cell, actually did worse when they spread to the lungs: median survival was about 14 months for chromophobe with lung metastases, compared with about 25 months for clear cell with lung metastases.¹⁴ This is a notable exception to the general rule that chromophobe kidney cancer is less aggressive. Clinicians who treat these rarer subtypes need to account for the specific site of metastasis, not just the histology alone.

On the molecular side, certain gene mutations found in clear cell tumors, particularly in BAP1, have been linked to a higher likelihood of presenting with metastatic disease and a trend toward shorter recurrence-free survival compared with PBRM1-mutated tumors.¹⁵ Tumor genomics are increasingly used alongside clinical risk scores to refine prognosis, though they have not yet fully entered routine practice at every center.

Circulating Tumor DNA as an Emerging Prognostic Tool

One of the more promising developments in kidney cancer monitoring involves measuring circulating tumor DNA (ctDNA), fragments of tumor genetic material that leak into the bloodstream. This is a rapidly evolving field, and results so far suggest ctDNA can provide real-time prognostic information beyond what imaging alone offers.

In surgically treated renal cell carcinoma patients, the presence of ctDNA after surgery was associated with a roughly threefold higher risk of relapse. Among patients who tested positive for ctDNA at any postoperative time point, the positive predictive value for relapse was 100%, meaning every patient who had detectable ctDNA after surgery eventually relapsed.¹⁶

In the metastatic setting, serial ctDNA monitoring provides additional layering. Patients whose ctDNA cleared or remained negative on therapy had significantly better progression-free survival than those whose ctDNA persisted or became positive, with the latter group facing roughly a threefold higher hazard of progression during treatment and an even steeper disadvantage during post-treatment surveillance.¹⁷ A Japanese nationwide genomic profiling project similarly found that a higher ctDNA tumor fraction was associated with shorter progression-free survival on first-line therapy, and this remained significant in multivariate analysis.¹⁸ The practical implication: ctDNA monitoring could eventually help oncologists identify patients who are responding well versus those who need an early treatment switch, before imaging shows visible growth.

The Rare Phenomenon of Spontaneous Regression

Kidney cancer is one of a small number of tumor types where spontaneous regression of metastases has been documented, and lung metastases account for most of these reported cases. After nephrectomy alone, without any systemic treatment, some patients have seen their lung nodules shrink or disappear.¹⁹ This has been noted since at least the late 1970s, with immunological mechanisms suspected as the likely explanation.²⁰

This is genuinely rare, estimated at well under 1% of cases, and no one should plan their care around the hope of spontaneous regression. But its existence reinforces that kidney cancer has an unusually active relationship with the immune system, which is one reason modern immunotherapy combinations have been so much more effective in this cancer than in many other solid tumors.

Recurrence After Nephrectomy and the Importance of Surveillance

Kidney cancer can recur in the lungs years or even decades after the original kidney surgery, which creates a long tail of uncertainty for patients who thought they were cured. Recurrence rates after nephrectomy for clinically localized disease range from about 20% to 40%.²¹ There is no universally agreed-upon surveillance protocol, but most guidelines call for periodic chest imaging (CT scans) for years after surgery, with the frequency tapering over time as the risk of late recurrence gradually declines.

This long surveillance window can be psychologically taxing. Quality-of-life research in metastatic renal cell carcinoma patients shows a measurable decline in self-reported health when disease progresses. In one study, average global health scores dropped from 69 before progression to 61 afterward on a standardized scale, with fatigue, pain, and shortness of breath being the symptoms most strongly associated with reduced quality of life.²² For patients with lung-only metastases who remain asymptomatic, quality of life can stay relatively preserved for long stretches, particularly if they are in a favorable risk group and their disease is being managed with well-tolerated therapy or active surveillance after local treatment.

When Lung Nodules Are Not What They Seem

A practical wrinkle that patients and clinicians face: not every lung nodule in a kidney cancer patient is a metastasis. Some turn out to be benign, and a small percentage are actually a separate primary lung cancer. In one series, about 2% of patients with metastatic renal cell carcinoma were later diagnosed with a distinct non-small-cell lung cancer, a figure that climbed to roughly 3.5% when looking only at those who already had pulmonary kidney cancer metastases.¹ Biopsy or careful imaging characteristics sometimes help distinguish between metastatic kidney cancer in the lung and a new lung primary, and the distinction matters because the treatment and prognosis are quite different for each.